Curvebeam Ai (CVB.AX) traded flat 0 % during a 24 hours period ending at 10:45 PM Central Europe on Monday 26th. One Curvebeam Ai stock can currently be bought for about AUD 0.02 on popular exchanges. Current supply of Curvebeam Ai stocks is 806.5 mn. Curvebeam Ai has a current market capitalization of AUD 16.1 mn and approximately AUD 73.4 k worth of Curvebeam Ai was traded on exchanges in the last 24 hours. Since last month end, Curvebeam Ai has traded -16 % down. Simple moving average of last 200 days is at AUD 0.04. The highest price of past 52 weeks was recorded at AUD 0.13 on 10/30/2025. 52 weeks low was at AUD 0.02 on 07/17/2026.

Summary of the latest news for Curvebeam Ai

CurveBeam AI Limited has filed an initial director’s interest notice with the Australian Securities Exchange. The filing, disclosed on 26 October 2026, names Daniel A. Pryor as the director who was appointed on 25 October 2026. Pryor’s disclosed holdings comprise a sizeable number of ordinary shares and a substantial block of share rights. No additional interests in securities held by other parties or contractual arrangements were reported. The submission follows the requirements of listing rule 3.19A.1 and section 205G of the Corporations Act, ensuring that relevant information is made available to the market and may become public through ASX disclosure mechanisms.

Here is how related stocks have performed in the past 24 hours:

  • Seastar Medical (ICU) traded down -15.44 % and now trades at USD 2.47. Seastar Medical has a market capitalisation of USD 12.7 mn.

  • Mobix Labs (MOBX) traded up 5.57 % and now trades at USD 0.76. Current market capitalisation for Mobix Labs is USD 12.9 mn.

  • Bionano Genomics (BNGO) traded down -4.24 % and now trades at USD 1.16. Bionano Genomics has a market capitalisation of USD 13.3 mn.

  • Pasithea Therapeutics (KTTA) traded down -8.99 % and now trades at USD 0.4. Current market capitalisation for Pasithea Therapeutics is USD 13.5 mn.

  • Tscan Therapeutics (TCRX) traded down -6.02 % and now trades at USD 0.19. Tscan Therapeutics has a market capitalisation of USD 13.3 mn.

About Curvebeam Ai

CurveBeam AI Limited is a health care technology company based in Melbourne, Australia. The company specializes in designing, manufacturing, and selling diagnostic cone beam CT scanners. Their platform offers point of care imaging solutions with artificial intelligence and deep learning AI, particularly focused on orthopedics and bone health (fragility fracture prevention). This technology aims to improve patient outcomes by providing more accurate and efficient imaging techniques. CurveBeam AI operates globally, and you can find more information about their products and services on their website, www.curvebeamai.com , or through trading on the ASX All Markets.